Decrease of alpha-crystallin A by miR-325-3p in retinal cells under blue light exposure
- PMID: 38997088
- PMCID: PMC11342174
- DOI: 10.1016/j.mocell.2024.100091
Decrease of alpha-crystallin A by miR-325-3p in retinal cells under blue light exposure
Abstract
Exposure to blue light can lead to retinal degeneration, causing adverse effects on eye health. Although the loss of retinal cells due to blue light exposure has been observed, the precise molecular mechanisms underlying this process remain poorly understood. In this study, we investigate the role of alpha-crystallin A (CRYAA) in neuro-retinal degeneration and their regulation by blue light. We observed significant apoptotic cell death in both the retina of rats and the cultured neuro-retinal cells. The expressions of Cryaa mRNA and protein were significantly downregulated in the retina exposed to blue light. We identified that miR-325-3p reduces Cryaa mRNA and protein by binding to its 3'-untranslated region. Upregulation of miR-325-3p destabilized Cryaa mRNA and suppresses CRYAA, whereas downregulation of miR-325-3p increased both expressions. Blue light-induced neuro-retinal cell death was alleviated by CRYAA overexpression. These results highlight the critical role of Cryaa mRNA and miR-325-3p molecular axis in blue light-induced retinal degeneration. Consequently, targeting CRYAA and miR-325-3p presents a potential strategy for protecting against blue light-induced retinal degeneration.
Keywords: Alpha-crystallin A; High-energy visible light; MicroRNAs; Neuro-retinal cell; Retina.
Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of Competing Interests The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Figures





References
-
- Andley U.P. Crystallins in the eye: function and pathology. Prog. Retin. Eye Res. 2007;26:78–98. - PubMed
-
- Arac A., Brownell S.E., Rothbard J.B., Chen C., Ko R.M., Pereira M.P., Albers G.W., Steinman L., Steinberg G.K. Systemic augmentation of alphaB-crystallin provides therapeutic benefit twelve hours post-stroke onset via immune modulation. Proc. Natl. Acad. Sci. U.S.A. 2011;108:13287–13292. - PMC - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources